A Phase 2 interventional study of Isatuximab SAR650984 in Warm Autoimmune Hemolytic Anemia (wAIHA), sponsored by Sanofi. Terminated at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-05.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States — 4 open to participants now, 9 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · United States.
Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, this one is the 23rd largest by enrollment of the 30 interventional ones that give a count, is one of 6 that started in 2021, is one of 14 in phase 2, and was the 18th registered.
103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.
Browse Anemia, Hemolytic, Autoimmune studies →4 of the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States are open now. Recruiting first, the newest first:
Sanofi · Sites in United States, Argentina, Austria and 15 more countries
Ages 18+
Lakefront Biotherapeutics West LLC · Sites in United States, Australia
Ages 18–75
Rigel Pharmaceuticals · Sites in United States, Australia, Austria and 15 more countries
Ages 18–100
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Denmark, Germany and 1 more country
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 18 · Phase 3 9
First in 1997; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 23 across 78 interventional studies indexed under Anemia, Hemolytic, Autoimmune.
Median enrollment 24 across the 30 interventional studies, 429 across the 1 observational. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 31 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 9 studies filed under Anemia, Hemolytic, Autoimmune — fewer than ten, so there is no comparison to draw.
1 of the studies in Anemia, Hemolytic, Autoimmune with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07083960Lakefront Biotherapeutics West LLCOM336 in Autoimmune Cytopenias | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objectives:
Secondary Objectives:
Part B
Parts A (all Cohorts) and B
28 weeks (including screening)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant must be ≥18 to years of age, inclusive, at the time of signing the .
Positive direct antiglobulin test (DAT) (IgG or IgG + complement C3d pattern or IgM warm autoantibodies (positive dual DAT)).
Exclusion criteria:
medical history or ongoing chronic illness that would jeopardize the safety of the participant or compromise the quality of the data derived from his or her participation in the study as determined by the Investigator.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2 doses of Isatuximab 140 milligrams (mg) (1 milliliter \[mL\]) via subcutaneous (SC) injection every 2 weeks (Q2W) on Day 1 and Day 15.
Drug: Isatuximab SAR650984
Participants received 6 doses of Isatuximab 280 mg (2 mL) via SC injection Q2W through Day 71.
Drug: Isatuximab SAR650984
Participants received 6 doses of Isatuximab 560 mg (4 mL) via SC injection Q2W through Day 71.
Drug: Isatuximab SAR650984
Participants were planned to receive 6 doses of Isatuximab up to 560 mg (4 mL) via SC injection Q2W through Day 71
Drug: Isatuximab SAR650984
Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) And Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred from the time of the first IMP administration up to 30 days (included) after the last IMP administration. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
Time frame: From first dose of study drug (Day 1) up to 30 days after last study intervention administration, approximately 101 days
Part A: Number of Participants With Potentially Clinically Significant Abnormality (PCSA): Hematology
Blood samples were collected to determine the hematology laboratory significant abnormalities. PCSA values: abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hemoglobin (Hb): ≤ 115 grams per Liter (g/L) (Male\[M\]); ≤ 95 g/L (Female\[F\]), ≥ 185 g/L (M); ≥ 165 g/L (F), Decrease from baseline ≥ 20 g/L; Hematocrit: ≤ 0.37 volume per volume (v/v) (M); ≤ 0.32 v/v (F), ≥ 0.55 v/v (M); ≥ 0.5 v/v (F); Erythrocyte Count: ≥ 6 x 10\^12 per Liter (/L); Platelet count: \< 100 x 10\^9/L, ≥ 700 x 10\^9/L; Leukocytes: \< 3 x 10\^9/L (Non-Black \[NB\]); \< 2 x 10\^9/L (Black \[B\]), ≥ 16 x 10\^9/L; Neutrophils: \< 1.5 x 10\^9/L (B); \< 1 x 10\^9/L (B); Lymphocytes: \> 4 x 10\^9/L; Monocytes: \> 0.7 x 10\^9/L; Basophils: \> 0.1 x 10\^9/L; Eosinophils: \> 0.5 x 10\^9/L or \> Upper limit of Normal (ULN) (if ULN ≥ 0.5 x 10\^9/L).
Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days
Part A: Number of Participants With PCSA: Clinical Chemistry And Electrolyte Parameters
Blood samples were collected to determine the clinical chemistry laboratory and electrolyte parameters significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Glucose: ≤ 3.9 millimoles per Liter (mmol/L) and \< Lower limit of normal (LLN), ≥ 11.1 mmol/L (unfasted); ≥ 7 mmol/L (fasted); Creatinine: ≥ 150 micromoles (µmol)/L, ≥ 30% change from baseline, ≥ 100% change from baseline, Alanine Aminotransferase (ALT): \> 3 ULN, \> 5 ULN, \> 10 ULN; Aspartate Aminotransferase (AST): \> 3 ULN; Alkaline Phosphatase (ALP): \> 1.5 ULN; Total Bilirubin: \> 1.5 ULN, \> 2 ULN; Sodium: ≤ 129 mmol/L, ≥ 160 mmol/L and Potassium: \< 3 mmol/L, ≥ 5.5 mmol/L.
Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days
Part A: Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis
Urine samples were collected to determine the urinalysis parameter significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: pH: ≤ 4.6 or ≥ 8.
Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days
Part A: Number of Participants With Potentially Clinically Significant Abnormality: Vital Signs
Vital signs were examined to determine the abnormalities. Vital signs included Sitting systolic blood pressure (SSBP), Sitting diastolic blood pressure (SDBP), Sitting heart rate (SHR) and weight. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: SSBP: ≤95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg; ≥160 mmHg and increase from baseline ≥20 mmHg; SDBP: ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; SHR: ≤ 50 beats per minute (bpm) and decrease from baseline ≥ 20 bpm, ≥120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% decrease from baseline, ≥5% increase from baseline.
Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days
Part B: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 85
Overall response rate was defined as the percentage of participants with a response (R) or complete response (CR) over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, Lactate dehydrogenase \[LDH\], haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks.
Time frame: Day 85
Part A: Cohorts 2 and 3: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 85 And Day 169
Overall response rate was defined as the percentage of participants with a R or CR over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, LDH, haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks
Time frame: Day 85 and Day 169
Part A: Cohorts 2 and 3: Percentage Of Participants With Durable Hemoglobin (Hb) Response By Day 169
Durable response was defined as Hb level ≥10 g/dL with an increase from baseline of ≥2 g/dL on three consecutive evaluable visits during the study period; with absence of transfusion and no rescue medication during the period of 3 consecutive visits and for at least 7 days (transfusions) and 4 weeks (rescue medication) prior to the first consecutive visit.
Time frame: From first dose of study drug (Day 1) up to end of study (Day 169)
Part A: Cohorts 2 and 3: Absolute Change From Baseline in Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Scale Score At Day 85 and Day 169
The FACIT-Fatigue scale is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher score (and positive change scores) indicated better functioning. Baseline was defined as the Day 1 pre-dose value.
Time frame: Baseline (Day 1), Day 85 and Day 169
Part A: Absolute Change From Baseline In Lactate Dehydrogenase (LDH) at 1, 2, 4, 8, 12, and 24 Weeks
Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: LDH. Baseline is defined as the last assessment value before IMP.
Time frame: Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Part A: Absolute Change From Baseline In Haptoglobin at 1, 2, 4, 8, 12, and 24 Weeks
Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Haptoglobin. Baseline was defined as the last assessment value before IMP.
Time frame: Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Part A: Absolute Change From Baseline In Reticulocytes at 1, 2, 4, 8, 12, and 24 Weeks
Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Reticulocytes. Baseline was defined as the last assessment value before IMP.
Time frame: Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Part A: Absolute Change From Baseline In Total Bilirubin at 1, 2, 4, 8, 12, and 24 Weeks
Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Total Bilirubin. Baseline was defined as the last assessment value before IMP.
Time frame: Cohort 1 : Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, and 12; Cohorts 2 and 3: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Part A: Maximum Observed Concentration (Cmax) Of Isatuximab
Blood samples were collected at the specified timepoints. Cmax was defined as maximum concentration observed after the first infusion. The non-compartmental pharmacokinetic (PK) analysis was performed.
Time frame: Post-dose on Day 1
Part A: Time to Reach Cmax (Tmax) of Isatuximab
Blood samples were collected at the specified timepoints. Tmax was defined as time to reach Cmax. The non-compartmental PK analysis was performed.
Time frame: Post-dose on Day 1
Part A: Area Under the Plasma Concentration Versus Time Curve Calculated Using the Trapezoidal Method From Time Zero to Time of the Last Concentration Observed Above the Lower Limit of Quantification (Clast) (AUClast) of Isatuximab
Blood samples were collected at the specified timepoints. AUClast was defined as area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to time of the Clast. The non-compartmental PK analysis was performed.
Time frame: Post-dose on Day 1
Part A: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of Isatuximab
Blood samples were collected at the specified timepoints. AUCtau was defined as area under the plasma concentration versus time curve over the dosing interval. The non-compartmental PK analysis was performed.
Time frame: Post-dose on Day 1
Part A: Mean Plasma Trough Concentration Of Isatuximab
Blood samples were collected at the specified timepoints. The non-compartmental Pharmacokinetic (PK) analysis was performed
Time frame: Post-dose on Days 15, 29, 43 and 57
Part A: Number Of Participants With Anti-Isatuximab Antibodies
Plasma samples were collected to evaluate antibodies to Isatuximab. Plasma samples were screened for antibodies binding to Isatuximab. Post-baseline positive, defined as Anti-drug antibody (ADA) that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Number of participants with positive ADA have been reported.
Time frame: Up to Days 169
Part B: Number of Participants With TEAEs And TESAEs
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred from the time of the first IMP administration up to 30 days (included) after the last IMP administration. A SAE is defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days
Part B: Number of Participants With PCSA: Hematology
Blood samples were planned to be collected to determine the hematology laboratory significant abnormalities. PCSA values: abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hb: ≤ 115 g/L (M); ≤ 95 g/L (F), ≥ 185 g/L (M); ≥ 165 g/L (F), Decrease from baseline ≥ 20 g/L; Hematocrit: ≤ 0.37 v/v (M); ≤ 0.32 v/v (F), ≥ 0.55 v/v (M); ≥ 0.5 v/v (F); Erythrocyte Count: ≥ 6 x 10\^12/L); Platelet count: \< 100 x 10\^9/L, ≥ 700 x 10\^9/L; Leukocytes: \< 3 x 10\^9/L (NB); \< 2 x 10\^9/L (B), ≥ 16 x 10\^9/L; Neutrophils: \< 1.5 x 10\^9/L (B); \< 1 x 10\^9/L (B); Lymphocytes: \> 4 x 10\^9/L; Monocytes: \> 0.7 x 10\^9/L; Basophils: \> 0.1 x 10\^9/L; Eosinophils: \> 0.5 x 10\^9/L or \> ULN (if ULN ≥ 0.5 x 10\^9/L).
Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days
Part B: Number of Participants With PCSA: Clinical Chemistry And Electrolyte Parameters
Blood samples were planned to be collected to determine the clinical chemistry laboratory and electrolyte parameters significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Glucose: ≤ 3.9 mmol/L and \< LLN, ≥ 11.1 mmol/L (unfasted); ≥ 7 mmol/L (fasted); Creatinine: ≥ 150 µmol/L, ≥ 30% change from baseline, ≥ 100% change from baseline, ALT: \> 3 ULN, \> 5 ULN, \> 10 ULN; AST: \> 3 ULN; ALP: \> 1.5 ULN; Total Bilirubin: \> 1.5 ULN, \> 2 ULN; Sodium: ≤ 129 mmol/L; ≥ 160 mmol/L; Potassium: \< 3 mmol/L, ≥ 5.5 mmol/L and Calcium
Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days
Part B: Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis
Urine samples were planned to be collected to determine the urinalysis parameter significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: pH ≤ 4.6 or ≥ 8.
Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days
Part B: Number of Participants With Potentially Clinically Significant Abnormality: Vital Signs
Vital signs were planned to be examined to determine the abnormalities. Vital signs included SSBP, SDBP, SHR and weight. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: SSBP: ≤ 95 mmHg and decrease from baseline ≥ 20 mmHg, ≥ 160 mmHg and increase from baseline ≥20 mmHg; SDBP: ≤ 45 mmHg and decrease from baseline ≥ 10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; SHR: ≤ 50 bpm and decrease from baseline ≥ 20 bpm, ≥ 120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% decrease from baseline, ≥5% increase from baseline.
Time frame: From first dose of study drug (Day 1) up to end of study, approximately 169 days
Part B: Percentage Of Participants With Durable Hemoglobin Response By Day 169
Durable response was defined as Hb level ≥10 g/dL with an increase from baseline of ≥2 g/dL on three consecutive evaluable visits during the study period; with absence of transfusion and no rescue medication during the period of 3 consecutive visits and for at least 7 days (transfusions) and 4 weeks (rescue medication) prior to the first consecutive visit.
Time frame: From first dose of study drug (Day 1) up to end of study (Day 169)
Part B: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 169
Overall response rate was defined as the percentage of participants with a R or CR over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, LDH, haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks
Time frame: Day 169
Part B: Absolute Change From Baseline In FACIT-Fatigue Scale Score At Day 85 And Day 169
The FACIT-Fatigue scale is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher score (and positive change scores) indicated better functioning. Baseline was defined as the Day 1 pre-dose value.
Time frame: Baseline (Day 1) and Day 85 and Day 169
Part B: Absolute Change From Baseline In LDH at 1, 2, 4, 8, 12, and 24 Weeks
Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: LDH. Baseline was defined as the last assessment value before IMP
Time frame: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Part B: Absolute Change From Baseline In Haptoglobin at 1, 2, 4, 8, 12, and 24 Weeks
Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Haptoglobin. Baseline was defined as the last assessment value before IMP
Time frame: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Part B: Absolute Change From Baseline In Reticulocytes at 1, 2, 4, 8, 12, and 24 Weeks
Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Reticulocytes. Baseline was defined as the last assessment value before IMP
Time frame: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Part B: Absolute Change From Baseline In Total Bilirubin at 1, 2, 4, 8, 12, and 24 Weeks
Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Total Bilirubin. Baseline was defined as the last assessment value before IMP
Time frame: Baseline (Day 1) and pre-dose at Weeks 1, 2, 4, 8, 12, and 24
Part B: Cmax Of Isatuximab
Blood samples were planned to be collected at the specified timepoints. Cmax was defined as maximum concentration observed after the first infusion.
Time frame: Post-dose on Day 1
Part B: AUCtau of Isatuximab
Blood samples were planned to be collected at the specified timepoints. AUCtau was defined as area under the plasma concentration versus time curve over the dosing interval.
Time frame: Post-dose on Day 1
Part B: Mean Plasma Trough Concentration Of Isatuximab
Blood samples were planned to be collected at the specified timepoints.
Time frame: Post-dose on Days 15, 29, 43 and 57
Part B: Number Of Participants With Anti-Isatuximab Antibodies
Plasma samples were planned to be collected to evaluate antibodies to Isatuximab. Plasma samples were planned to be screened for antibodies binding to Isatuximab. Post-baseline positive, defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.
Time frame: Up to Days 169
The study was conducted at 6 centers in 6 countries. A total of 10 participants were screened from 09 September 2021 to 19 December 2022, of which 2 participants were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.
| Milestone | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 | Part B: Isatuximab up to 560 mg SC Q2W x6 |
|---|---|---|---|---|
| Started | 3 | 3 | 2 | 0 |
| Participants who completed the study treatment period | 3 | 2 | 1 | 0 |
| Completed | 0 | 3 | 1 | 0 |
| Not completed | 3 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Switch of cohort due to retreatment criteria met | 1 | 0 | 0 | 0 |
| Withdrew: As per principal investigator (pi) decision | 1 | 0 | 0 | 0 |
| Withdrew: Early discontinuation as per pi | 1 | 0 | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred from the time of the first IMP administration up to 30 days (included) after the last IMP administration. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
| Participants | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Any TEAEs | 2 | 2 | 2 |
| Any TESAEs | 1 | 0 | 1 |
Blood samples were collected to determine the hematology laboratory significant abnormalities. PCSA values: abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hemoglobin (Hb): ≤ 115 grams per Liter (g/L) (Male\[M\]); ≤ 95 g/L (Female\[F\]), ≥ 185 g/L (M); ≥ 165 g/L (F), Decrease from baseline ≥ 20 g/L; Hematocrit: ≤ 0.37 volume per volume (v/v) (M); ≤ 0.32 v/v (F), ≥ 0.55 v/v (M); ≥ 0.5 v/v (F); Erythrocyte Count: ≥ 6 x 10\^12 per Liter (/L); Platelet count: \< 100 x 10\^9/L, ≥ 700 x 10\^9/L; Leukocytes: \< 3 x 10\^9/L (Non-Black \[NB\]); \< 2 x 10\^9/L (Black \[B\]), ≥ 16 x 10\^9/L; Neutrophils: \< 1.5 x 10\^9/L (B); \< 1 x 10\^9/L (B); Lymphocytes: \> 4 x 10\^9/L; Monocytes: \> 0.7 x 10\^9/L; Basophils: \> 0.1 x 10\^9/L; Eosinophils: \> 0.5 x 10\^9/L or \> Upper limit of Normal (ULN) (if ULN ≥ 0.5 x 10\^9/L).
| Participants | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Hb: ≤ 115 g/L (M); ≤ 95 g/L (F) | 3 | 3 | 2 |
| Hb: ≥ 185 g/L (M); ≥ 165 g/L (F), | 0 | 0 | 0 |
| Hb: Decrease from baseline ≥ 20 g/L | 0 | 1 | 0 |
| Hematocrit: ≤ 0.37 v/v (M); ≤ 0.32 v/v (F) | 3 | 3 | 2 |
| Hematocrit: ≥ 0.55 v/v (M); ≥ 0.5 v/v (F) | 0 | 0 | 0 |
| Erythrocyte Count: ≥ 6 x 10^12/L | 0 | 0 | 0 |
| Platelet Count: < 100 x 10^9/L | 0 | 0 | 0 |
| Platelet Count: ≥ 700 x 10^9/L | 0 | 1 | 0 |
| Leukocytes: < 3 x 10^9/L (NB); < 2 x 10^9/L (B) | 0 | 0 | 1 |
| Leukocytes: ≥ 16 x 10^9/L | 2 | 1 | 1 |
| Neutrophils: < 1.5 x 10^9/L (NB); < 1 x 10^9/L (B) | 0 | 0 | 1 |
| Lymphocytes: > 4 x 10^9/L | 1 | 0 | 0 |
| Monocytes: > 0.7 x 10^9/L | 2 | 1 | 1 |
| Basophils: > 0.1 x 10^9/L | 2 | 1 | 1 |
| Eosinophils: > 0.5 x 10^9/L or > ULN (if ULN ≥ 0.5 x 10^9/L) | 1 | 0 | 1 |
Blood samples were collected to determine the clinical chemistry laboratory and electrolyte parameters significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Glucose: ≤ 3.9 millimoles per Liter (mmol/L) and \< Lower limit of normal (LLN), ≥ 11.1 mmol/L (unfasted); ≥ 7 mmol/L (fasted); Creatinine: ≥ 150 micromoles (µmol)/L, ≥ 30% change from baseline, ≥ 100% change from baseline, Alanine Aminotransferase (ALT): \> 3 ULN, \> 5 ULN, \> 10 ULN; Aspartate Aminotransferase (AST): \> 3 ULN; Alkaline Phosphatase (ALP): \> 1.5 ULN; Total Bilirubin: \> 1.5 ULN, \> 2 ULN; Sodium: ≤ 129 mmol/L, ≥ 160 mmol/L and Potassium: \< 3 mmol/L, ≥ 5.5 mmol/L.
| Participants | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Glucose: ≤ 3.9 mmol/L and < LLN | 0 | 0 | 1 |
| Glucose: ≥ 11.1 mmol/L (unfasted); ≥ 7 mmol/L (fasted) | 0 | 1 | 0 |
| Creatinine: ≥ 150 µmol/L | 0 | 0 | 0 |
| Creatinine: ≥ 30% change from baseline | 2 | 0 | 0 |
| Creatinine: ≥ 100% change from baseline | 1 | 0 | 0 |
| ALT: > 3 ULN | 1 | 0 | 1 |
| ALT: > 5 ULN | 1 | 0 | 0 |
| ALT: > 10 ULN | 0 | 0 | 0 |
| AST: > 3 ULN | 0 | 0 | 0 |
| ALP: > 1.5 ULN | 0 | 0 | 0 |
| Total Bilirubin: > 1.5 ULN | 3 | 2 | 2 |
| Total Bilirubin: > 2 ULN | 3 | 2 | 2 |
| Sodium: ≤ 129 mmol/L | 0 | 0 | 0 |
| Sodium: ≥ 160 mmol/L | 0 | 0 | 0 |
| Potassium: < 3 mmol/L | 0 | 0 | 0 |
| Potassium: ≥ 5.5 mmol/L | 0 | 0 | 0 |
Urine samples were collected to determine the urinalysis parameter significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: pH: ≤ 4.6 or ≥ 8.
| Participants | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| pH: ≤ 4.6 | 0 | 0 | 0 |
| pH: ≥ 8 | 0 | 0 | 0 |
Vital signs were examined to determine the abnormalities. Vital signs included Sitting systolic blood pressure (SSBP), Sitting diastolic blood pressure (SDBP), Sitting heart rate (SHR) and weight. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: SSBP: ≤95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg; ≥160 mmHg and increase from baseline ≥20 mmHg; SDBP: ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; SHR: ≤ 50 beats per minute (bpm) and decrease from baseline ≥ 20 bpm, ≥120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% decrease from baseline, ≥5% increase from baseline.
| Participants | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| SSBP: ≤95 mmHg and decrease from baseline ≥20 mmHg | 0 | 0 | 2 |
| SSBP: ≥160 mmHg and increase from baseline ≥20 mmHg | 1 | 0 | 0 |
| SDBP: ≤45 mmHg and decrease from baseline ≥10 mmHg | 0 | 0 | 2 |
| SDBP: ≥ 110 mmHg and increase from baseline ≥ 10 mmHg | 0 | 0 | 0 |
| SHR: ≤ 50 bpm and decrease from baseline ≥ 20 bpm | 0 | 0 | 0 |
| SHR: ≥ 120 bpm and increase from baseline ≥ 20 bpm | 0 | 0 | 1 |
| Weight: ≥5% decrease from baseline | 0 | 0 | 0 |
| Weight: ≥ 5% increase from baseline | 1 | 0 | 1 |
Overall response rate was defined as the percentage of participants with a response (R) or complete response (CR) over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, Lactate dehydrogenase \[LDH\], haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks.
No measurements were reported for this outcome.
Overall response rate was defined as the percentage of participants with a R or CR over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, LDH, haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks
| Percentage of participants | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|
| Day 85 | 0.0 | 50.0 |
| Day 169 | 0.0 | 0.0 |
Durable response was defined as Hb level ≥10 g/dL with an increase from baseline of ≥2 g/dL on three consecutive evaluable visits during the study period; with absence of transfusion and no rescue medication during the period of 3 consecutive visits and for at least 7 days (transfusions) and 4 weeks (rescue medication) prior to the first consecutive visit.
| Percentage of participants | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|
| Part A: Cohorts 2 and 3: Percentage Of Participants With Durable Hemoglobin (Hb) Response By Day 169 | 0 | 50 |
The FACIT-Fatigue scale is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher score (and positive change scores) indicated better functioning. Baseline was defined as the Day 1 pre-dose value.
| Score on a scale | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|
| Day 85 | 7.3 ± 9.3 | 12.0 ± NA |
| Day 169 | 1.0 ± NA | 4.0 ± NA |
Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: LDH. Baseline is defined as the last assessment value before IMP.
| International Units per Liter (IU/L) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Pre-dose at Week 1 | 84.0 ± 347.5 | -67.3 ± 81.4 | -264.0 ± 196.6 |
| Pre-dose at Week 2 | 13.0 ± 192.3 | -110.7 ± 126.5 | -331.5 ± 236.9 |
| Pre-dose at Week 4 | -342.3 ± 130.2 | -124.0 ± 133.3 | -234.5 ± 105.4 |
| Pre-dose at Week 8 | -355.5 ± 444.8 | -136.0 ± 349.9 | -309.5 ± 231.2 |
| Pre-dose at Week 12 | -134.0 ± 183.8 | -22.0 ± 201.8 | -146.0 ± NA |
| Pre-dose at Week 24 | — | 278.7 ± 601.0 | -135.0 ± NA |
Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Haptoglobin. Baseline was defined as the last assessment value before IMP.
| Grams per Liter (g/L) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Pre-dose at Week 1 | 0.000 ± 0.000 | 0.030 ± 0.026 | -0.005 ± 0.007 |
| Pre-dose at Week 2 | 0.000 ± 0.000 | 0.000 ± 0.000 | -0.010 ± NA |
| Pre-dose at Week 4 | 0.000 ± 0.000 | -0.016 ± 0.028 | -0.005 ± 0.007 |
| Pre-dose at Week 8 | 0.000 ± 0.000 | -0.025 ± 0.035 | 2.995 ± 4.250 |
| Pre-dose at Week 12 | 0.000 ± NA | -0.025 ± 0.035 | -0.010 ± NA |
| Pre-dose at Week 24 | — | -0.022 ± 0.038 | -0.050 ± NA |
Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Reticulocytes. Baseline was defined as the last assessment value before IMP.
| 10^9 cells per Liter | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Pre-dose at Week 1 | 86.000 ± NA | -25.533 ± 49.878 | -158.400 ± NA |
| Pre-dose at Week 2 | 43.000 ± NA | -29.733 ± 36.258 | -347.400 ± NA |
| Pre-dose at Week 4 | -51.000 ± NA | -36.833 ± 34.662 | -370.300 ± NA |
| Pre-dose at Week 8 | -9.000 ± NA | -31.733 ± 84.835 | -280.300 ± NA |
| Pre-dose at Week 12 | 44.000 ± NA | -6.133 ± 33.198 | -250.600 ± NA |
| Pre-dose at Week 24 | — | -126.933 ± 70.273 | 9.900 ± NA |
Blood samples were collected to evaluate the effect of Isatuximab on marker of hemolysis: Total Bilirubin. Baseline was defined as the last assessment value before IMP.
| Micromoles per Liter (μmol/L) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Pre-dose at Week 1 | -8.52 ± 19.00 | -7.01 ± 3.12 | -15.00 ± 2.83 |
| Pre-dose at Week 2 | 2.45 ± 15.88 | -6.38 ± 1.10 | -13.00 ± 4.24 |
| Pre-dose at Week 4 | -18.26 ± 31.86 | -2.00 ± 1.78 | -8.50 ± 7.78 |
| Pre-dose at Week 8 | -14.31 ± 5.89 | -8.21 ± 17.53 | -14.50 ± 10.61 |
| Pre-dose at Week 12 | 0.70 ± 18.47 | 3.65 ± 11.83 | -4.00 ± NA |
| Pre-dose at Week 24 | — | 0.06 ± 9.08 | 17.00 ± NA |
Blood samples were collected at the specified timepoints. Cmax was defined as maximum concentration observed after the first infusion. The non-compartmental pharmacokinetic (PK) analysis was performed.
| Micrograms per milliliter (μg/mL) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Part A: Maximum Observed Concentration (Cmax) Of Isatuximab | 3.64 ± 1.19 | 7.41 ± 6.29 | 151 ± 121 |
Blood samples were collected at the specified timepoints. Tmax was defined as time to reach Cmax. The non-compartmental PK analysis was performed.
| Hours (h) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Part A: Time to Reach Cmax (Tmax) of Isatuximab | 89.50 (89.35 to 96.33) | 92.68 (48.58 to 119.17) | 202.69 (94.80 to 310.58) |
Blood samples were collected at the specified timepoints. AUClast was defined as area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to time of the Clast. The non-compartmental PK analysis was performed.
| Hours*micrograms per milliliter(h*μg/mL) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Part A: Area Under the Plasma Concentration Versus Time Curve Calculated Using the Trapezoidal Method From Time Zero to Time of the Last Concentration Observed Above the Lower Limit of Quantification (Clast) (AUClast) of Isatuximab | 540 ± 30.0 | 879 ± 99.0 | 23900 ± 41.0 |
Blood samples were collected at the specified timepoints. AUCtau was defined as area under the plasma concentration versus time curve over the dosing interval. The non-compartmental PK analysis was performed.
| Hours*micrograms per milliliter(h*μg/mL) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Part A: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of Isatuximab | 560 ± 171 | 1370 ± 1350 | 17800 ± NA |
Blood samples were collected at the specified timepoints. The non-compartmental Pharmacokinetic (PK) analysis was performed
| Micrograms per milliliter (μg/mL) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Day 15 | 0.0114 ± 0.0140 | 0.678 ± 0.994 | 140 ± 137 |
| Day 29 | 0.167 ± 0.270 | 7.30 ± 7.13 | 134 ± 62.3 |
| Day 43 | 0.00111 ± 0.00131 | 6.69 ± 5.90 | 62.0 ± 87.7 |
| Day 57 | NA ± NA | 10.7 ± 4.08 | 146 ± NA |
Plasma samples were collected to evaluate antibodies to Isatuximab. Plasma samples were screened for antibodies binding to Isatuximab. Post-baseline positive, defined as Anti-drug antibody (ADA) that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Number of participants with positive ADA have been reported.
| Participants | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 |
|---|---|---|---|
| Part A: Number Of Participants With Anti-Isatuximab Antibodies | 1 | 1 | 0 |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred from the time of the first IMP administration up to 30 days (included) after the last IMP administration. A SAE is defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
No measurements were reported for this outcome.
Blood samples were planned to be collected to determine the hematology laboratory significant abnormalities. PCSA values: abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hb: ≤ 115 g/L (M); ≤ 95 g/L (F), ≥ 185 g/L (M); ≥ 165 g/L (F), Decrease from baseline ≥ 20 g/L; Hematocrit: ≤ 0.37 v/v (M); ≤ 0.32 v/v (F), ≥ 0.55 v/v (M); ≥ 0.5 v/v (F); Erythrocyte Count: ≥ 6 x 10\^12/L); Platelet count: \< 100 x 10\^9/L, ≥ 700 x 10\^9/L; Leukocytes: \< 3 x 10\^9/L (NB); \< 2 x 10\^9/L (B), ≥ 16 x 10\^9/L; Neutrophils: \< 1.5 x 10\^9/L (B); \< 1 x 10\^9/L (B); Lymphocytes: \> 4 x 10\^9/L; Monocytes: \> 0.7 x 10\^9/L; Basophils: \> 0.1 x 10\^9/L; Eosinophils: \> 0.5 x 10\^9/L or \> ULN (if ULN ≥ 0.5 x 10\^9/L).
No measurements were reported for this outcome.
Blood samples were planned to be collected to determine the clinical chemistry laboratory and electrolyte parameters significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Glucose: ≤ 3.9 mmol/L and \< LLN, ≥ 11.1 mmol/L (unfasted); ≥ 7 mmol/L (fasted); Creatinine: ≥ 150 µmol/L, ≥ 30% change from baseline, ≥ 100% change from baseline, ALT: \> 3 ULN, \> 5 ULN, \> 10 ULN; AST: \> 3 ULN; ALP: \> 1.5 ULN; Total Bilirubin: \> 1.5 ULN, \> 2 ULN; Sodium: ≤ 129 mmol/L; ≥ 160 mmol/L; Potassium: \< 3 mmol/L, ≥ 5.5 mmol/L and Calcium
No measurements were reported for this outcome.
Urine samples were planned to be collected to determine the urinalysis parameter significant abnormalities. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: pH ≤ 4.6 or ≥ 8.
No measurements were reported for this outcome.
Vital signs were planned to be examined to determine the abnormalities. Vital signs included SSBP, SDBP, SHR and weight. PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: SSBP: ≤ 95 mmHg and decrease from baseline ≥ 20 mmHg, ≥ 160 mmHg and increase from baseline ≥20 mmHg; SDBP: ≤ 45 mmHg and decrease from baseline ≥ 10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; SHR: ≤ 50 bpm and decrease from baseline ≥ 20 bpm, ≥ 120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% decrease from baseline, ≥5% increase from baseline.
No measurements were reported for this outcome.
Durable response was defined as Hb level ≥10 g/dL with an increase from baseline of ≥2 g/dL on three consecutive evaluable visits during the study period; with absence of transfusion and no rescue medication during the period of 3 consecutive visits and for at least 7 days (transfusions) and 4 weeks (rescue medication) prior to the first consecutive visit.
No measurements were reported for this outcome.
Overall response rate was defined as the percentage of participants with a R or CR over the evaluable participants. R was defined as an increase in Hb by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days and absence of rescue medications in the past 4 weeks. Biochemical evidence of hemolysis might still be present. CR was defined as Hb ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, LDH, haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and absence of rescue medication in the past 4 weeks
No measurements were reported for this outcome.
The FACIT-Fatigue scale is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher score (and positive change scores) indicated better functioning. Baseline was defined as the Day 1 pre-dose value.
No measurements were reported for this outcome.
Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: LDH. Baseline was defined as the last assessment value before IMP
No measurements were reported for this outcome.
Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Haptoglobin. Baseline was defined as the last assessment value before IMP
No measurements were reported for this outcome.
Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Reticulocytes. Baseline was defined as the last assessment value before IMP
No measurements were reported for this outcome.
Blood samples were planned to be collected to evaluate the effect of Isatuximab on marker of hemolysis: Total Bilirubin. Baseline was defined as the last assessment value before IMP
No measurements were reported for this outcome.
Blood samples were planned to be collected at the specified timepoints. Cmax was defined as maximum concentration observed after the first infusion.
No measurements were reported for this outcome.
Blood samples were planned to be collected at the specified timepoints. AUCtau was defined as area under the plasma concentration versus time curve over the dosing interval.
No measurements were reported for this outcome.
Blood samples were planned to be collected at the specified timepoints.
No measurements were reported for this outcome.
Plasma samples were planned to be collected to evaluate antibodies to Isatuximab. Plasma samples were planned to be screened for antibodies binding to Isatuximab. Post-baseline positive, defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.
No measurements were reported for this outcome.
Collected over TEAEs were collected from first dose of study drug (Day 1) up to 30 days after last study intervention administration, approximately 101 days. All-cause mortality (deaths) were collected from first dose of study drug (Day 1) up to end of study, approximately 169 days.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | 0/3 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Part B: Isatuximab up to 560 mg SC Q2W x6 | — | — | — |
| Event | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 | Part B: Isatuximab up to 560 mg SC Q2W x6 |
|---|---|---|---|---|
| SepsisInfections and infestations | 0/3 | 0/3 | 1/2 | — |
| Infusion Related ReactionInjury, poisoning and procedural complications | 0/3 | 0/3 | 1/2 | — |
| Alanine Aminotransferase IncreasedInvestigations | 1/3 | 0/3 | 1/2 | — |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/3 | 0/2 | — |
| Liver InjuryHepatobiliary disorders | 1/3 | 0/3 | 0/2 | — |
| Acute Kidney InjuryRenal and urinary disorders | 1/3 | 0/3 | 0/2 | — |
| Event | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 | Part B: Isatuximab up to 560 mg SC Q2W x6 |
|---|---|---|---|---|
| HeadacheNervous system disorders | 2/3 | 0/3 | 0/2 | — |
| ToothacheGastrointestinal disorders | 0/3 | 0/3 | 1/2 | — |
| Oedema PeripheralGeneral disorders | 0/3 | 1/3 | 1/2 | — |
| Urinary Tract InfectionInfections and infestations | 0/3 | 0/3 | 1/2 | — |
| Back PainMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 1/2 | — |
| SplenomegalyBlood and lymphatic system disorders | 1/3 | 0/3 | 0/2 | — |
| Covid-19Infections and infestations | 0/3 | 1/3 | 0/2 | — |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 1/3 | 0/2 | — |
Safety population included all participants exposed to the investigational medicinal product (IMP) (regardless of the amount of treatment administered). The study was prematurely terminated based on strategic sponsor decision during Part A; not driven by any safety concerns, hence Part B was not conducted, and no analysis was performed.
| Age, Continuous(Years) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 | Part B: Isatuximab up to 560 mg SC Q2W x6 | Total |
|---|---|---|---|---|---|
| Mean | 59.3 ± 24.7 | 44.7 ± 7.6 | 47.5 ± 30.4 | — | 50.9 ± 19.3 |
| Age, Customized(Participants) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 | Part B: Isatuximab up to 560 mg SC Q2W x6 | Total |
|---|---|---|---|---|---|
| 18 to 64 years | 1 | 3 | 1 | 0 | 5 |
| 65 to 84 years | 2 | 0 | 1 | 0 | 3 |
| Sex: Female, Male(Participants) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 | Part B: Isatuximab up to 560 mg SC Q2W x6 | Total |
|---|---|---|---|---|---|
| Female | 1 | 3 | 1 | 0 | 5 |
| Male | 2 | 0 | 1 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2 | Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6 | Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6 | Part B: Isatuximab up to 560 mg SC Q2W x6 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 3 | 2 | 0 | 8 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Sep 2021 to primary completion in Jun 2023, 21 months.
Results were first posted in Aug 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isatuximab
Anemia, Hemolytic, Autoimmune →